Form 10-Q
------------------------------------------------------------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
FORM 10-Q
------------------------------------------------------------------------------------------------------------------------------------
{X} QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2002
Commission File No. 0-19131
MedImmune, Inc.
(Exact name of registrant as specified in its charter)
Delaware 52-1555759
(State or other jurisdiction of (I. R. S. Employer
incorporation or organization) Identification No.)
35 West Watkins Mill Road, Gaithersburg, MD 20878
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (301) 417-0770
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file
such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]
As of August 7, 2002, 250,823,654 shares of Common Stock, par value $0.01 per share, were outstanding.
MEDIMMUNE, INC.
Index to Form 10-Q
Part I Financial Information Page
----
Item 1. Consolidated Financial Statements
Consolidated Balance Sheets 1-2
Consolidated Statements of Operations 3
Condensed Consolidated Statements of Cash Flows 4-5
Notes to Consolidated Financial Statements 6-15
Item 2. Management's Discussion and Analysis of Financial Condition
and Results of Operations 16-26
Item 3. Quantitative and Qualitative Disclosures About Market Risk 26
Part II Other Information
Item 1. Legal Proceedings 28
Item 2. Changes in Securities 29
Item 3. Defaults upon Senior Securities 30
Item 4. Submission of Matters to a Vote of Security Holders 30
Item 5. Other Information 30
Item 6. Exhibits and Reports on Form 8-K 30
Synagis, CytoGam, Ethyol, RespiGam, Vitaxin and NeuTrexin are registered trademarks of the Company. FluMist and Numax are
trademarks of the Company.
ITEM 1. FINANCIAL STATEMENTS
MEDIMMUNE, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)
June 30, December 31,
2002 2001
---------- ----------
ASSETS: (Unaudited)
Cash and cash equivalents $89,677 $171,255
Marketable securities 553,991 227,067
Trade receivables, net -- 108,902
Inventory, net 53,447 50,836
Deferred tax assets 27,517 27,280
Other current assets 15,353 9,063
---------- ----------
Total Current Assets 739,985 594,403
Marketable securities 710,384 389,368
Property and equipment, net 163,259 95,402
Deferred tax assets, net 261,201 136,361
Intangible assets, net 121,595 --
Goodwill 14,220 --
Other assets 7,958 3,852
---------- ----------
Total Assets $2,018,602 $1,219,386
========== ==========
LIABILITIES AND SHAREHOLDERS' EQUITY:
Accounts payable $26,214 $5,873
Accrued expenses 92,027 94,965
Product royalties payable 36,767 47,720
Deferred revenue 10,790 13,839
Other current liabilities 8,122 2,149
---------- ----------
Total Current Liabilities 173,920 164,546
Long-term debt 228,644 8,791
Other liabilities 21,177 1,776
---------- ----------
Total Liabilities 423,741 175,113
---------- ----------
Commitments and Contingencies
SHAREHOLDERS' EQUITY:
Preferred stock, $.01 par value; authorized
5,524,525 shares; none issued or outstanding -- --
Common stock, $.01 par value; authorized
320,000,000 shares; issued and outstanding
250,671,284 at June 30, 2002 and
214,484,084 at December 31, 2001 2,507 2,145
Paid-in capital 2,604,137 891,627
Deferred compensation (15,877) --
Accumulated (deficit) earnings (1,004,439) 141,875
Accumulated other comprehensive income 8,533 8,626
---------- ---------
Total Shareholders' Equity 1,594,861 1,044,273
---------- ----------
Total Liabilities and Shareholders' Equity $2,018,602 $1,219,386
========== ==========
The accompanying notes are an integral part of these financial statements.
MEDIMMUNE, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(in thousands, except share data)
For the For the
three months ended six months ended
June 30, June 30,
2002 2001 2002 2001
-------- ------ ----------- --------
Revenues:
Product sales $57,330 $28,315 $377,998 $263,517
Other revenue 6,392 5,055 15,357 15,049
-------- ------- ----------- --------
Total revenues 63,722 33,370 393,355 278,566
-------- ------- ----------- --------
Costs and expenses:
Cost of sales 15,642 7,127 95,519 59,930
Research and development 34,545 21,693 78,614 40,392
Selling, general and administrative 47,354 24,202 142,994 83,942
Other operating expenses 22,152 3,487 43,993 5,595
Acquired in-process research and development -- -- 1,179,321 --
-------- ------- ----------- --------
Total expenses 119,693 56,509 1,540,441 189,859
-------- ------- ----------- --------
Operating (loss) income (55,971) (23,139) (1,147,086) 88,707
Interest income 11,863 8,989 23,797 19,232
Interest expense (1,876) (149) (4,638) (299)
-------- ------- ----------- --------
(Loss) earnings before income taxes (45,984) (14,299) (1,127,927) 107,640
(Benefit) provision for income taxes (16,528) (5,076) 18,387 38,212
-------- ------- ----------- --------
Net (loss) earnings $(29,456) $(9,223) $(1,146,314) $69,428
======== ======= =========== ========
Basic (loss) earnings per share $(0.12) $(0.04) $(4.62) $0.33
======== ======= =========== ========
Shares used in calculation of basic (loss) earnings per share 250,161 213,131 248,110 212,656
======== ======= =========== ========
Diluted (loss) earnings per share $(0.12) $(0.04) $(4.62) $0.32
======== ======= =========== ========
Shares used in calculation of diluted (loss) earnings per share 250,161 213,131 248,110 219,878
======== ======= =========== ========
The accompanying notes are an integral part of these financial statements.
MEDIMMUNE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(in thousands)
For the
Six months ended
June 30,
2002 2001
----------- ---------
CASH FLOWS FROM OPERATING ACTIVITIES:
Net (loss) earnings $(1,146,314) $69,428
Noncash items:
Acquired in-process research and development 1,179,321 --
Deferred taxes 22,383 34,349
Deferred revenue (4,502) (8,654)
Capitalized interest (279) --
Depreciation and amortization 16,415 4,572
Amortization of premium (discount) on marketable securities 4,480 (3,361)
Amortization of deferred compensation 11,823 --
Amortization of bond premium (886) --
Accretion of interest on long-term obligation 534 --
Change in reserve for inventory (121) 4,251
Change in allowances for trade accounts receivable (937) (8,052)
Decrease in restructuring liability for non-cash employee termination costs 9,234 --
Other 862 29
Other changes in assets and liabilities, net of effects of Aviron acquisition 63,005 76,626
----------- ---------
Net cash provided by operating activities 155,018 169,188
----------- ---------
CASH FLOWS FROM INVESTING ACTIVITIES:
Increase in marketable securities (379,863) (197,098)
Net cash acquired in acquisition of Aviron 146,853 --
Capital expenditures (37,708) (3,546)
Minority interest investments (3,734) (1,500)
----------- ---------
Net cash used in investing activities (274,452) (202,144)
----------- ---------
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of common stock
and exercise of stock options 38,146 16,444
Decrease in long-term debt (389) (439)
----------- ---------
Net cash provided by financing activities 37,757 16,005
----------- ---------
Effect of exchange rate changes on cash 99 (155)
Net decrease in cash and cash equivalents (81,578) (17,106)
Cash and cash equivalents at beginning of period 171,255 84,974
----------- ---------
Cash and cash equivalents at end of period $ 89,677 $ 67,868
=========== =========
Supplemental schedule of noncash investing and financing activities:
During January 2002, the Company acquired 100% of the outstanding capital stock of Aviron through an exchange offer and merger
transaction. The Company exchanged approximately 34.0 million of its common shares for all of the outstanding shares of Aviron
common stock and assumed Aviron's outstanding options and warrants, for which approximately 7.0 million additional shares of the
Company's common stock are issuable. The estimated fair value of the net assets acquired was $1,635.1 million, and included $1,179.3
million of acquired research and development assets that were charged to current period results at the date of acquisition and
$211.4 million of 5 1/4% convertible subordinated notes due in 2008.
The accompanying notes are an integral part of these financial statements.
MEDIMMUNE, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
General
The financial information presented in the consolidated financial statements at June 30, 2002 and for the three months and six
months ended June 30, 2002 and 2001 is unaudited. In the opinion of the Company's management, the financial information presented
herein contains all adjustments (which consist only of normal recurring adjustments) necessary for a fair presentation of results
for the interim periods presented. Interim results are not necessarily indicative of results for an entire year or for any
subsequent interim period. These consolidated financial statements should be read in conjunction with the Company's annual report on
Form 10-K for the year ended December 31, 2001.
Organization
MedImmune, Inc., a Delaware corporation (together with its subsidiaries, the "Company"), is a biotechnology company headquartered in
Gaithersburg, Maryland. The Company currently has five products on the market and maintains a diverse product portfolio. The
Company is focused on using advances in immunology and other biological sciences to develop important new products that address
significant medical needs in areas such as infectious diseases, immune regulation and oncology.
During January 2002, the Company completed its acquisition of Aviron, subsequently renamed MedImmune Vaccines, Inc., a
biopharmaceutical company headquartered in Mountain View, California, through an exchange offer and merger transaction. The
acquisition was accounted for as a purchase, and the results of operations of MedImmune Vaccines are included in the results of the
Company effective January 10, 2002.
New Accounting Standard
Effective January 1, 2002, the Company adopted SFAS No. 142 ("SFAS 142"), "Goodwill and Other Intangible Assets." SFAS 142 addresses
financial accounting and reporting for acquired goodwill and other intangible assets and supersedes APB Opinion No. 17, "Intangible
Assets." Under SFAS 142, goodwill and intangible assets with indefinite lives are no longer amortized but are reviewed at least
annually for impairment. The amortization provisions of SFAS 142 apply to goodwill and intangible assets acquired after June 30,
2001. Inasmuch as the Company had no recorded goodwill or intangible assets prior to the January 2002 acquisition of Aviron, the
adoption of SFAS 142 did not have an impact on the Company's financial position, results of operations, or cash flows.
Change in Accounting Method
For new contracts executed after January 1, 2002, the Company has changed its accounting method for contract revenues such that the
Company may recognize contract revenues associated with substantive at risk performance milestones when the milestone is achieved,
when no future service obligation is attendant to that milestone, and when the related revenue is due and payable under the
milestone payment method. The change in accounting principle was made to more closely reflect the essence of the contractual
obligations the Company enters into with collaborative partners. Specifically, milestone payments are often directly related to the
completed portion (an achieved milestone) of the arrangement and therefore revenues are earned and recognized as the milestones are
is achieved. Also, the new method is prevalent in the industry in which the Company operates. The effect on earnings and earnings
per share for the three months and six months ended June 30, 2002 is not material. In circumstances where it is not appropriate to
use the milestone payment method, the Company will continue to use the contingency-adjusted performance model.
Significant Accounting Policies
Contract Revenues - For contracts executed prior to January 1, 2002, contract revenues are recognized over the fixed term of the
contract as the related expenses are incurred. Upfront fees and milestone payments under collaborative agreements are recognized
when they are earned in accordance with the applicable performance requirements and contractual terms, using the
contingency-adjusted performance model for revenue recognition. Under this method, payments received that are related to future
performance are deferred and recorded as revenues as they are earned over specified future performance periods. The amount of
revenue recognized during each period is based on a percentage-of-completion model based on actual costs incurred relative to the
total projected costs. Recognized revenues are subject to revisions as the collaboration efforts progress and estimated costs to
complete are revised. For new contracts executed after January 1, 2002, the Company uses the milestone payment method when all
milestones to be received under contractual arrangements are determined to be substantive, at risk and the culmination of an
earnings process. Substantive milestones are payments that are conditioned upon an event requiring substantive effort, when the
amount of the milestone is reasonable relative to the time, effort and risk involved in achieving the milestone and when the
milestones are reasonable relative to each other and the amount of any up-front payment. If all of these criteria are not met, then
the Company will use the contingency adjusted performance (percentage of completion) model.
Acquisition
On January 10, 2002, the Company completed its acquisition of Aviron through an exchange offer and merger transaction pursuant to
the definitive merger agreement between the two parties dated December 2, 2001. Aviron, subsequently renamed MedImmune Vaccines,
Inc., is a biopharmaceutical company headquartered in Mountain View, California, focused on prevention of disease through innovative
vaccine technologies. Its lead product candidate is FluMist, a live, attenuated virus vaccine delivered as a nasal mist for the
prevention of influenza. FluMist has not been approved by the FDA.
Under the terms of the agreement, the Company exchanged approximately 34.0 million of its common shares for 100% of the outstanding
common stock of Aviron. Additionally, approximately 7.0 million shares are issuable upon the exercise of Aviron's outstanding
options and warrants. Holders of Aviron's $200 million of 5 1/4% convertible subordinated notes due in 2008 may convert the notes
into a total of approximately 3.4 million shares of the Company's common stock, based on a conversion price of $58.14 per share.
The acquisition was accounted for as a purchase and, accordingly, the results of Aviron's operations have been included with the
Company's since the acquisition date.
In the period ended June 30, 2002, the Company recorded a purchase price adjustment resulting from a final reconciliation of Aviron
registered shares of common stock as of the acquisition date and a refinement to the calculation of unearned compensation for
terminated employees, which resulted in a net decrease of $1.4 million to the purchase price and a corresponding decrease to
goodwill. This adjustment had no material impact on the Company's results of operations for the three months and six months ended
June 30, 2002. The revised aggregate purchase consideration was approximately $1.6 billion, as follows (in thousands):
Common stock $1,497,271
Assumption of Aviron's options and warrants,
less intrinsic value of unvested portion 128,027
Transaction costs 9,758
----------
$1,635,056
==========
The value of common shares issued was $44.10 per share, based on the closing market price of the Company's common stock on November
30, 2001, the last business day prior to the signing of the merger agreement. The fair value of Aviron's options and warrants
assumed in the transaction was estimated using the Black-Scholes option pricing model.
The following table summarizes the estimated fair values (in thousands) of the assets acquired and liabilities assumed at the date
of acquisition, as revised. The Company is in the process of determining the fair value of certain tangible assets and liabilities;
thus, the allocation of the purchase price is subject to refinement:
Assets:
Cash and marketable securities $417,507
Other current assets 24,911
Other long-term assets 42,494
Deferred tax assets 133,970
Intangible assets 129,000
In-process research and development 1,179,321
Goodwill 14,220
----------
Total assets: 1,941,423
----------
Liabilities:
Current liabilities 49,847
Restructuring liability 15,894
Long-term debt 211,380
Long-term obligations 28,745
Other liabilities 501
----------
Total liabilities 306,367
----------
Net assets acquired: $1,635,056
==========
Of the $129.0 million of acquired intangible assets, $90.0 million was assigned to Aviron's worldwide collaborative agreement with
Wyeth for the development, manufacturing, distribution, marketing, promotion, and sale of FluMist, which is subject to amortization
over its estimated useful life of approximately 11 years. The Company estimated the fair value of the Wyeth agreement using the sum
of the probability-adjusted scenarios under the income approach. In applying this method, the Company relied on revenue assumptions,
profitability assumptions and anticipated approval dates. The remaining $39.0 million was assigned to Aviron's contract
manufacturing agreement with Evans Vaccines Limited, which is subject to amortization over its estimated useful life of
approximately four years. The Company estimated the fair value of the Evans agreement using the cost approach, which is based on the
theory that a prudent investor would pay no more for an asset than the amount for which the asset could be replaced. In its
analysis, the Company reduced replacement cost for such factors as physical deterioration and functional or economic obsolescence.
Approximately $1,179.3 million of the purchase price was allocated to acquired research and development assets that were written off
at the date of acquisition as a separate component of the Company's results of operations in accordance with FASB Interpretation No.
4, "Applicability of FASB Statement No. 2 to Business Combinations Accounted for by the Purchase Method." The amount represents the
fair value of purchased in-process technology for projects that, as of the date of the acquisition, had not yet reached
technological feasibility and had no alternative future use, primarily Aviron's lead product candidate, FluMist, which has not been
approved by the FDA.
Approximately $14.2 million in goodwill was recognized in the revised allocation of the purchase price, none of which is expected to
be deductible for tax purposes. Through June 30, 2002, the Company recorded a purchase price adjustment of $1.4 million and a
reversal to the restructuring liability of $0.1 million (discussed below), which resulted in a net reduction to goodwill of $1.5
million. In accordance with SFAS 142, the goodwill recognized in the transaction is not amortized, but will be reviewed for
impairment on an annual basis.
Included in the revised allocation of acquisition cost is a restructuring liability of $15.9 million for estimated costs associated
with the Company's restructuring plan. The restructuring plan was originally formulated and announced to employees in December 2001,
to consolidate and restructure certain functions, including the involuntary termination of eight Aviron executives and 52 other
Aviron employees from various functions and levels. Through June 30, 2002, the Company decided to retain two of those 52 positions
and recorded a charge reversal of $0.1 million for the related severance and accelerated vesting of stock options, which resulted in
a reduction to goodwill. As revised, the restructuring liability consists of $5.3 million for contractual severance payments, $9.5
million for accelerated vesting of stock options to employees and executives, as dictated by their employment agreements and the
provisions of the various stock options plans, and approximately $1.1 million for estimated costs for vacant lease space which is
not expected to be used by the Company during the remaining term of the lease as a result of the Company's plan to consolidate
certain functions. Subsequent adjustments to the allocation of the acquisition cost related to the true-up of severance and other
restructuring costs are not expected to be significant. During the three months ended June 30, 2002, actual severance payments of
$0.4 million, compensation expense of $0.3 million for the accelerated vesting of stock options for terminated executives and
employees, and rent expense of $0.2 million for vacant lease space were charged against the restructuring liability. During the six
months ended June 30, 2002, actual severance payments of $5.1 million, compensation expense of $9.2 million for the accelerated
vesting of stock options for terminated executives and employees, and rent expense of $0.2 million for vacant lease space were
charged against the restructuring liability. As of June 30, 2002, the balance of the restructuring liability was $1.4 million.
The restructuring liability activity through June 30, 2002 is summarized as follows (in thousands):
Original Accrual at Restructuring Restructuring Balance at
January 10, 2002 Charges Incurred Charge Reversals June 30, 2002
---------------- ---------------- ---------------- -------------
Employee severance costs $ 5,365 $ (5,056) $(43) $ 266
Acceleration of employee stock options 9,520 (9,234) (52) 234
Other facility-related costs 1,105 (239) -- 866
------- -------- ---- ------
Total $15,990 $(14,529) $(95) $1,366
======= ======== ==== ======
Included in the allocation of acquisition cost were accrued transaction costs of $9.8 million, which primarily consist of investment
banking, accounting and legal fees incurred by the Company. For the period ended June 30, 2002, there were no significant
adjustments to accrued transaction costs. As of June 30, 2002, the balance of accrued transaction costs was immaterial.
The following unaudited pro forma condensed combined supplemental data present the revenues, net earnings and earnings per share of
the combined entity as though the business combination had been completed as of January 1, 2002 and 2001, respectively. The
unaudited pro forma condensed combined supplemental data gives effect to actual operating results prior to the acquisition, adjusted
to include the pro forma effect of amortization of intangibles, deferred stock compensation costs, the elimination of the
non-recurring charge for acquired in-process research and development, the tax effects to the pro forma adjustments and the
recognition of the tax benefits arising from Aviron's net loss for the 2001 period. The unaudited pro forma condensed combined
supplemental data are not necessarily an indication of the results that would have been achieved had the transaction been
consummated as of the dates indicated or that may be achieved in the future.
Three months ended Three months ended Six months ended Six months ended
June 30, 2002 June 30, 2001 June 30, 2002 June 30, 2001
------------- ------------- ------------- -------------
Revenues $63,722 $38,698 $393,355 $287,721
Net earnings (29,456) (31,981) 33,007(1) 27,531
Basic earnings per share (0.12) (0.13) 0.13(1) 0.11
Diluted earnings per share (0.12) (0.13) 0.13(1) 0.11
(1) Excludes a non-recurring charge of $1,179.3 million for acquired in-process research and development.
Long-term Debt
Following the Company's acquisition of Aviron, Aviron (subsequently renamed MedImmune Vaccines) remains obligated for its
outstanding indebtedness, which included $200.0 million aggregate principal amount of 5 1/4% Convertible Subordinated Notes (the
"Notes") due 2008. Approximately $211.4 million of the acquisition cost was allocated to the Notes, which represents the fair value
as of the acquisition date, based on quoted market prices. The Notes are convertible into an aggregate of 3.4 million shares of the
Company's common stock, based on a conversion price of $58.14, at any time on or before January 15, 2008. MedImmune Vaccines may
redeem the Notes beginning in February 2004, at redemption prices declining from 103% of their principal amount in 2004 to 100% in
2008, plus accrued interest. Interest is payable semi-annually in arrears in cash on February 1 and August 1 each year.
Derivative Instruments and Hedging Activities
The Company adopted SFAS 133, "Accounting for Derivative Instruments and Hedging Activities", on January 1, 2001.
The Company purchases inventory from a foreign vendor and pays the vendor in a foreign currency. This exposes the Company to foreign
currency exchange rate risk, which is monitored by the Company as part of its overall risk-management program. The Company uses
foreign-currency forward-exchange contracts to hedge these risks. SFAS 133 requires that all derivatives be recorded on the balance
sheet at fair value. Changes in the value of foreign-currency forward-exchange contracts are recorded in other comprehensive income
and recognized in earnings when the hedged forecasted transaction occurs.
The Company accounts for its derivatives as foreign-currency cash-flow hedges and is required to recognize any ineffectiveness on
hedging transactions as interest income or expense in the statement of operations. For the three months and six months ended June
30, 2002, gains or losses for ineffective hedges were insignificant. As of June 30, 2002, net deferred gains on derivative
instruments of $0.4 million, net of tax, in accumulated other comprehensive income are expected to be reclassified to earnings in
the next 12 months in conjunction with the sale of the related inventory. The maximum term over which the Company is hedging its
exposures to the variability of cash flows is 12 months.
Accounts Receivable Due to the seasonal nature of the Company's primary product, Synagis, a significant decrease in product sales
and trade accounts receivable occurred in the second quarter of 2002. In addition, reserve balances which exist at June 30, 2002 for
government rebate allowances relating to Synagis sales that occurred during the 2001/2002 season are higher than the offsetting
trade receivables balances, due to the later processing cycle by certain states for these rebates. As a result of these factors,
trade accounts receivable at June 30, 2002 carries a net credit balance. This net credit balance has been reclassified to accounts
payable for financial statement presentation.
Inventory
Inventory, net of reserves, is comprised of the following (in thousands):
June 30, December 31,
2002 2001
------- --------
Raw Materials $21,076 $16,805
Work in Process 21,561 13,731
Finished Goods 10,969 22,155
------- -------
53,606 52,691
Less noncurrent (159) (1,855)
------- -------
$53,447 $50,836
======= =======
Noncurrent inventory at June 30, 2002 and December 31, 2001 is comprised of some of the Company's raw plasma and certain CytoGam
production lots that are being tested for long-term stability which are not expected to be available for sale within the next 12
months.
Inventory balances are net of reserves for RespiGam inventory, for which minimal product sales are expected to result for the
foreseeable future. In April 2002, the Company reduced the inventory and reserve balances by $3.4 million upon the disposal of
expired product. RespiGam inventory and reserve balances were $1.7 million and $0.6 million, respectively, at June 30, 2002, versus
$4.9 million and $4.2 million, respectively, at December 31, 2001.
The Company has commenced production of inventory in connection with its proposed launch of FluMist. FluMist has not yet been
approved by the FDA. Accordingly, the Company recorded a full reserve for such inventory produced through June 30, 2002, which
resulted in a charge to other operating expense of approximately $18.0 million, in recognition of management's assessment that it
currently appears probable that such inventory materials will reach their expiration dates if FDA approval is not received in 2002.
Earnings per Share
The Company computes earnings per share in accordance with Statement of Financial Accounting Standards No. 128, "Earnings Per
Share." Basic earnings per share is computed based on the weighted average number of common shares outstanding during the period.
Diluted earnings per share is computed based on the weighted average shares outstanding adjusted for all dilutive potential common
shares. The dilutive impact, if any, of common stock equivalents outstanding during the period, including outstanding stock options
and warrants, is measured by the treasury stock method. The dilutive impact, if any, of the Notes is measured using the if-converted
method. Common stock equivalents are not included in periods where there is a loss as they are anti-dilutive. The following is a
reconciliation of the denominator of the diluted EPS computation for the periods reported. There are no reconciling items to the
numerator for the EPS computation for the periods reported.
Three months ended Three months ended Six months ended Six months ended
June 30, 2002 June 30, 2001 June 30, 2002 June 30, 2001
------------- ------------- ------------- -------------
Denominator:
Weighted average shares
outstanding 250,161 213,131 248,110 212,656
Effect of dilutive securities:
Stock options, warrants, and Notes -- -- -- 7,222
-------- -------- -------- --------
Denominator for diluted EPS 250,161 213,131 248,110 219,878
======== ======== ======== ========
The Company incurred net losses for the three months ended June 30, 2002 and 2001 and for the six months ended June 30, 2002, and,
accordingly, did not assume exercise or conversion of total common share equivalents of 5,641,435, 6,757,968, and 6,671,355 for
those periods, respectively, because to do so would be anti-dilutive. Options to purchase 6,775,861 shares of common stock with
prices ranging from $40.25 to $83.25 per share that were outstanding during the six months ended June 30, 2001 were not included in
the computation of diluted earnings per share because they were anti-dilutive.
Income Taxes
Income tax (benefit) expense for the three months and six months ended June 30, 2002 was ($16.5) million and $18.4 million,
respectively. Excluding the Company's write-off of purchased in-process research and development and other insignificant items,
which are not tax deductible, income tax expense as a percentage of pre-tax income for the six months ended June 30, 2002 was 35.7%.
During the six months ended June 30, 2002, the Company recognized credits for research and development expenditures and credits
earned for Orphan Drug status of certain research and development expenses, resulting in a reduction from the statutory rate of
37.0%.
Comprehensive (Loss) Income
Comprehensive (loss) income is comprised of net (loss) earnings and other comprehensive (loss) income. Other comprehensive (loss)
income includes certain changes in equity that are excluded from net (loss) earnings, such as translation adjustments, unrealized
holding gains and losses on available-for-sale marketable securities, and gains and losses on hedging instruments.
Comprehensive loss for the three months ended June 30, 2002 was $20.3 million versus $9.2 million for the comparable period in 2001.
Comprehensive (loss) income for the six months ended June 30, 2002 was $(1,146.4) million versus $65.6 million for the comparable
period in 2001. A significant component of other comprehensive income for the three months ended June 30, 2002 relates to net
unrealized holding gains on available-for-sale marketable securities of approximately $7.2 million, net of tax, versus net
unrealized holding gains of $0.3 million, net of tax, for the three months ended June 30, 2001. The Company maintains an investment,
which is subject to other-than-temporary impairment, in a company with which it previously formed a strategic alliance, which is
carried at its fair value, with unrealized holding gains and losses included in other comprehensive income (loss). Due to market
volatility associated with this investment, the value of the Company's investment has fluctuated significantly since the company's
initial public offering, and may continue to do so in the future.
Property and Equipment
During March 2002, the Company paid approximately $13.4 million to acquire 11 acres of land in Gaithersburg, Maryland, which will
serve as the site of the Company's new corporate headquarters. Additionally, the Company has options to purchase an additional 14
acres of land. The Company has contracted with a designer and general contractor for the construction of the first phase of the new
facility, at a total estimated cost of $85 million. Construction began during March 2002. As of June 30, 2002, approximately $4.5
million of engineering and construction costs related to Phase I of the new headquarters are included in construction in progress.
The Company expects to take occupancy of the first phase of construction, which will feature a complex totaling 218,000 square feet,
in the fall of 2003.
Minority Interest Investments
In connection with its research and development collaborations, the Company holds minority interests in companies having operations
or technology in areas within its strategic focus. The investments are maintained on the cost or equity method of accounting,
according to the facts and circumstances of the individual investment. Under either method, the investments are subject to
adjustment for other-than-temporary impairments. Additionally, for investments carried on the equity method, the Company's
proportionate share of the investee's gains or losses are recorded on a quarterly basis. For minority interests maintained in
publicly traded companies, the Company's investment is maintained as available-for-sale securities. Due to the highly volatile share
prices of these investments, the investments are subject to unrealized holding gains or losses.
Collaborative Arrangements
Wyeth
In January 1999, Aviron signed a worldwide collaborative agreement with Wyeth Lederle Vaccines, a subsidiary of Wyeth, for the
development, manufacturing, distribution, marketing, promotion, and sale of FluMist. Under this agreement, Wyeth has exclusive
worldwide rights to market FluMist, excluding Korea, Australia, New Zealand and some South Pacific countries. The two companies have
agreed to co-promote FluMist in the U.S. Wyeth holds the marketing rights in the U.S. for an initial term of seven years from the
first commercial sale of FluMist in the U.S. and outside the U.S. (with the exclusions noted above) for an initial term of eight
years from the first commercial sale of FluMist outside the U.S. Wyeth has the option to extend its rights both in the U.S. and
internationally for an additional four years, the aggregate of which could result in payments to the Company in ranging from $145
million to $400 million. Under the terms of the agreement with Wyeth, the two companies are to collaborate on the regulatory,
clinical and marketing programs for FluMist within the United States.
As a part of the collaboration, the Company is to receive certain payments related to the achievement of key milestones and events
for FluMist. In January 2001, Aviron received $15.5 million from Wyeth related to the acceptance by the FDA for the filing of the
BLA for FluMist on December 28, 2000. Potential milestone payments to the Company from Wyeth include: $20 million for approval in
the U.S.; $20 million for advisory body recommendations and expanded label claims; up to $25 million in supply goal payments, up to
$17.5 million for FDA approval of use in second and third target populations; $10 million for the submission of a license
application in Europe; a $27.5 million payment for the approval of a liquid formulation of FluMist, and up to $50 million upon
licensure in international regions. Additionally, Wyeth has committed to provide the Company with up to 420.0 million in financing,
contingent upon regulatory approval of FluMist. The total potential value for the license fees, milestones, financing support and
term extension options that the Company could receive from Wyeth could range from $300 million to $600 million.
Under the terms of the agreement, Wyeth will distribute FluMist and record all product sales. The Company will receive approximately
50% of FluMist revenues, paid in the form of product transfer payments and royalties. These payments are higher in the U.S. than
internationally. The Company incurs expenses to manufacture, supply and co-promote FluMist. Wyeth reimburses the Company for a
portion of the product's clinical development expenses and has agreed to spend up to $100 million for sales and marketing of FluMist
over the first three years of commercialization in the United States.
Evans Vaccines Limited
In July 1999, Aviron entered into an agreement with a division of Celltech Group Plc, which was later acquired by PowderJect
Pharmaceuticals Plc and is now called Evans Vaccines Limited ("Evans"), for the manufacture of key components of FluMist,
specifically the bulk manufacture of monovalents and diluent, as well as use of the manufacturing facilities. During October 2000,
Aviron restructured its agreement with Evans in order to gain direct control over FluMist manufacturing operations. Aviron obtained
responsibility for bulk manufacture of FluMist in Evans' Speke, U.K. facility, hired approximately 100 Evans employees who had been
working on FluMist, and entered into subleases through June 2006 for the FluMist manufacturing areas on the existing site. In
connection with the restructuring of the manufacturing agreement, Aviron made an initial payment of $15.0 million and a payment of
$3.9 million in September 2001. The Company is obligated to make four additional annual payments of $3.9 million in September 2002
through September 2005, which is included in long-term debt in the accompanying consolidated balance sheet as of June 30, 2002. The
Company is also obligated to make other additional payments totaling $19.0 million (included in other liabilities in the
accompanying consolidated balance sheets as of June 30, 2002), which will be paid over the term of the agreement based on net sales
of FluMist, if and when approved for marketing, with the unpaid balance, if any, due January 2006. Evans also received warrants for
which 67,899 shares of the Company's common stock are issuable at an exercise price of $44.19 per share. In addition, the Company is
obligated to make payments during the term of the agreement of $225,000 per year for the use of the Aviron unit in the Evans
manufacturing plant, payments up to an aggregate of $3.0 million for attaining specific milestones, and payments for other support
services based on the costs of these services incurred. The Company expenses rent and other support services as the costs are
incurred and expenses milestones as they become due.
Legal Proceedings
In 1998, MediGene AG ("MediGene") initiated a legal action against Loyola University of Chicago ("Loyola") and the Company in the
U.S. District Court for the Northern District of Illinois alleging, among other things, breach of contract and tortious interference
by the Company with an alleged prospective business relationship between MediGene and Loyola. The claims relate to human
papillomavirus vaccine technology allegedly covered by contracts between MediGene and the Company and by a license agreement from
Loyola to the Company, under which the Company granted a sublicense to GlaxoSmithKline. MediGene seeks damages from the Company
ranging from $31.3 million to $86.9 million based on the tortious interference claim, and/or damages ranging from $10.2 million to
$31.3 million based on the breach of contract claim. MediGene also seeks ownership of the patents in question, as well as recission
of the Company's license agreement from Loyola or rights as a third-party beneficiary thereof. On December 22, 2000 and March 15,
2001, the District Court granted summary judgment motions in favor of the Company on all claims. The District Court ordered entry of
final judgment in favor of the Company on March 19, 2002. On March 27, 2002 MediGene filed a notice of appeal to the United States
Court of Appeals for the Federal Circuit. On or about June 27, 2002, the Federal Circuit Court transferred the appeal to the United
States Court of Appeals for the Seventh Circuit. MediGene's brief will be due August 12, 2002 and Loyola and the Company's brief
will be due September 11, 2002.
In October 2000, Celltech Chiroscience Limited ("Celltech") commenced a legal proceeding against the Company in the U.K. High Court
of Justice, Chancery Division, Patents Court. Celltech alleges that the Company failed to pay royalties with respect to its sales of
Synagis as required by a license agreement dated January 19, 1998. Under the agreement, the Company obtained from Celltech a
worldwide license to make, use and/or sell product under a patent (and related applications) pertaining to humanized antibodies. In
the proceeding, Celltech seeks payment of a 2% royalty based on net sales of Synagis sold or manufactured in the United States, with
interest, and certain costs, including attorney's fees. The Company has filed answering papers denying that any royalties are due on
the basis that Celltech's U.S. patent does not cover Synagis and has sought dismissal of the case on the grounds that the legal
doctrine of prosecution history estoppel prevents Celltech from claiming that its patent covers Synagis. On July 20, 2001, the High
Court of Justice ordered a hearing, which is scheduled to begin on October 1, 2002, on whether it will dismiss Celltech's case on
this basis. On November 29, 2001, the Company received a letter from counsel for Celltech enclosing a copy of a patent granted by
the European Patent Office on November 14, 2001. That letter requested various information concerning the manufacture and sale of
Synagis in Europe and sought confirmation that the Company would pay royalties on such sales pursuant to the license agreement dated
January 19, 1998. As of August 9, 2002, the Company had not made the royalty payments that were the subject of Celltech's letter,
and Celltech had not initiated any legal proceeding against the Company based on its European patent.
On December 18, 2001, Genentech, Inc. ("Genentech") announced that it had been granted a patent relating to certain methods and
compositions used to produce antibodies by recombinant DNA technology. In June 1997, in anticipation of any potential impact the
issuance of Genentech's patent could have on the production of Synagis, the Company obtained a license to this patent. The Company
has received from Genentech a letter, dated January 7, 2002, stating that Genentech expects to receive from the Company royalty
payments pursuant to such license. The Company is in the process of evaluating whether any valid claim of Genentech's patent, as
recently issued, covers production of Synagis. If so, the Company would pay royalties to Genentech on U.S. net sales of Synagis
commencing December 18, 2001. Pending resolution of this issue, the Company has made certain royalty payments to Genentech under
protest and with reservation of all of its rights. The Company is also evaluating whether any of its other antibody-based product
candidates, if and when approved for marketing by the U.S. Food and Drug Administration, could require a license under the Genentech
patent.
On February 28, 1996, Ichthyol Gesellschaft Cordes, Hermanni&Co. ("Ichthyol Gesellschaft") filed a complaint for refrain,
information and damages with the Regional Court of Hamburg against MedImmune Oncology on the grounds of trademark infringement in
respect of the use of the trademark "Ethyol" in Germany. No monetary amount is currently being sought in the litigation by
Ichthyol. Ichthyol is seeking injunctive relief against the use of the trademark Ethyol in Germany. The suit was dismissed on
January 29, 1997 by the Regional Court of Hamburg. Ichthyol Gesellschaft filed an appeal and a judgment was rendered in favor of
MedImmune Oncology in the appellate proceedings. In January 1999, Ichthyol Gesellschaft filed an appeal on points of law with the
Federal Court of Justice, and in June 1999, Ichthyol Gesellschaft filed the grounds for the appeal on points of law. By judgment of
May 3, 2001, the Federal Court of Justice reversed the judgment of the Higher Regional Court and remitted the case to that court for
another hearing. By order of December l9, 2001, the Higher Regional Court ordered Ichthyol to make further submissions concerning
the relevant facts and legal questions. Ichthyol recently filed its submissions. Another hearing will probably be held this fall.
The Company is currently involved in a dispute over the RSV License Agreement ("License Agreement") between the Company and
University of Massachusetts Biologic Laboratories ("MBL"), executed in 1989. Under the License Agreement, the Company granted MBL an
exclusive, royalty free license to "make, have made, use and sell" the Company's monoclonal antibody for RSV for use only in the
Commonwealth of Massachusetts and the State of Maine. The Company further agreed to transfer to MBL sufficient information and to
provide sufficient technical assistance to enable MBL to apply the Company's monoclonal antibody to MBL's manufacturing operations.
MBL now alleges that the Company has not provided sufficient information or sufficient technical assistance to enable MBL to
manufacture the Company's monoclonal antibody for RSV. In addition, MBL has claimed that the Company's Distribution Agreement with
Abbott International, Ltd. ("Abbott"), under which Abbott is the exclusive distributor of Synagis overseas, constitutes a
"sub-license" under the terms of the License Agreement and thus MBL claims a right to a larger share of the proceeds derived by the
Company from the Distribution Agreement. The Company disputes the allegations made by MBL and believes MBL's claims to be without
merit. The Company and MBL are currently in the process of mediating their dispute to determine whether a mutually agreeable
solution can be achieved. There can be no assurance that this dispute can be resolved without litigation.
On April 5, 2002, the Company filed a suit against Centocor, Inc. ("Centocor") in the United States District Court for the District
of Maryland. The Company currently pays Centocor a royalty for sales of Synagis made or sold in the United States pursuant to a
patent Sublicense Agreement between the parties dated as of September 15, 2000 (the "Sublicense Agreement"). In the litigation, the
Company seeks a declaratory judgment that it has no obligation to continue paying royalties to Centocor on the basis that the patent
is invalid, unenforceable and does not cover Synagis. Additionally, the Company seeks an injunction preventing Centocor from
enforcing this patent. On July 1, 2002, Centocor moved to dismiss this action on the basis that it did not include the Trustees of
Columbia University in the City of New York ("Columbia") and the Board of Trustees of the Leland Stanford University ("Stanford"),
as the owners of the patent. On July 9, 2002, Centocor, Columbia and Stanford initiated an action against the Company in the United
States District Court for the Northern District of California. In the California litigation, Centocor, Columbia and Stanford seek a
declaratory judgment that the patent at issue in the Sublicense Agreement is valid and enforceable and that the Company would be
liable for patent infringement but for the Sublicense Agreement, as well as a declaratory judgment that the Sublicense Agreement is
enforceable. There can be no assurance that the Company will be successful in this litigation.
After consultation with its counsel, the Company believes that it has meritorious defenses to the claims against it referred to
above and is determined to defend its position vigorously. While it is impossible to predict with certainty the eventual outcome of
these proceedings, the Company believes they are unlikely to have a material adverse effect on its financial position but might have
a material adverse effect on its results of operations for a particular period.
ITEM 2.
MEDIMMUNE, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
GENERAL
During January 2002, we acquired Aviron, a biopharmaceutical company focused on prevention of disease through innovative vaccine
technologies. Aviron was subsequently renamed MedImmune Vaccines, Inc. We accounted for the acquisition under the purchase method of
accounting and have included MedImmune Vaccines' operating results in our consolidated operating results beginning on January 10,
2002.
CRITICAL ACCOUNTING POLICIES AND ESTIMATES
For a more detailed discussion of our critical accounting policies and estimates, please refer to Part II, Item 7 "Management's
Discussion and Analysis of Financial Condition Results of Operations" in our 2001 Annual Report on Form 10-K.
Contract Revenues - For contracts executed prior to January 1, 2002, we recognize revenue from upfront and milestone payments under
collaborative agreements using the contingency-adjusted performance model for revenue recognition. Under this method, payments
received that are related to future performance are deferred and recorded as revenues as they are earned over specified future
performance periods. The amount of revenue recognized during each period is based on a percentage-of-completion model of actual
costs incurred relative to the total projected costs to be incurred under the collaborative agreement. When the performance criteria
for a non-refundable milestone payment are met, the cost of the effort that has been incurred to date is divided by the total
projected costs under the development arrangement (i.e., ratio of performance), and revenue is recognized for that milestone to the
extent of the ratio of performance to date. We followed this method since reasonably dependable estimates of the revenue and costs
applicable to various stages of a collaboration agreement could be made. Recognized revenues are subject to revisions as the
collaboration efforts progress and estimated costs to complete are revised. Revisions in revenue estimates are recorded to income in
the period in which the facts that give rise to the revision become known.
For new contracts executed after January 1, 2002, the Company uses the milestone payment method when all milestones to be received
under contractual arrangements are determined to be substantive, at risk and the culmination of an earnings process. Substantive
milestones are payments that are conditioned upon an event requiring substantive effort, when the amount of the milestone is
reasonable relative to the time, effort and risk involved in achieving the milestone and when the milestones are reasonable relative
to each other and the amount of any up-front payment. If all of these criteria are not met, then the Company will use the
contingency adjusted performance (percentage of completion) model. This constitutes a change in accounting principle and was made to
more closely reflect the essence of the contractual obligations the Company enters into with collaborative partners. Specifically,
milestone payments are often times directly related to the completed portion (an achieved milestone) of the arrangement and
therefore revenues are earned and recognized as the milestones are achieved. Additionally, the new method is prevalent in our
industry and is used by most other companies in our peer group. The effect on earnings and earnings per share for the three months
and six months ended June 30, 2002 is not material. The milestone payment method may not be applicable to all new contracts, in
which case, the Company would revert to the contingency-adjusted performance model for revenue recognition.
Acquired In-Process Research and Development - We recorded a charge of $1,179.3 million during the six-month period ended June 30,
2002 for the write-off of purchased in-process research and development in conjunction with our acquisition of Aviron. The write-off
represents the fair value of purchased in-process technologies at the acquisition date, calculated utilizing the sum of the
probability-adjusted scenarios under the income approach. This method is based upon management's estimates of the probability of FDA
approval and commercial success for FluMist. As with all biotechnology products, the probability of FDA approval and commercial
success for any particular research and development project is highly uncertain. Management's projections were based on assumptions,
which may or may not remain valid for the relevant period, including the estimated impact of four "key" factors: price per dose;
dose volumes; launch date; and the potential failure of the frozen or liquid formulations of FluMist. Based on current information,
management believes that the estimates and assumptions underlying the fair value analysis are substantially accurate.
Inventory Reserves - The Company has commenced production of inventory in connection with its proposed launch of FluMist. FluMist
has not yet been approved by the FDA. Accordingly, the Company recorded a full reserve for such inventory produced through June 30,
2002, which resulted in a charge to other operating expense of approximately $18.0 million, in recognition of management's
assessment that it currently appears probable that such inventory materials will reach their expiration dates if FDA approval is not
received in 2002. Should FluMist be approved for the 2002/2003 flu season, any inventory sold would have no carrying value and as
such, margins would appear more favorable than the Company would anticipate in future periods.
RESULTS OF OPERATIONS
THREE MONTHS ENDED JUNE 30, 2002 AND 2001
Product Sales -
Product Sales (In Millions) 2002 2001
----- -----
Synagis $32.5 $15.0
Ethyol $16.6 $3.1
Other Products $8.2 $10.2
----- -----
TOTAL $57.3 $28.3
===== =====
We recorded product sales of $57.3 million in the second quarter of 2002, a 103% increase over 2001 levels of $28.3 million, due to
increased sales of Synagis and Ethyol. Synagis, our largest product, accounted for approximately 57% of our 2002 and 53% of our 2001
second quarter product sales. Sales of Synagis for the quarter ended June 30, 2002 increased 116% over the comparable 2001 period.
Contributing to the growth in 2002 sales was a 253% increase in domestic Synagis sales to $27.1 million in 2002 from $7.7 million in
2001. The growth was attributable to increased demand in the United States, resulting in a 245% increase in domestic sales unit
volumes, as well as a 3% domestic price increase which took effect in June 2002. International sales of Synagis decreased 27% to
$5.4 million in the 2002 quarter versus $7.4 million in the 2001 quarter, reflecting reduced shipments to our international
distributor. The Company's international sales volume decreased 60% during the 2002 quarter as compared to the 2001 quarter. The
Company believes that the decrease is due to reductions in the inventory stocking levels of our international distributor, Abbott
International ("Abbott"), rather than reduced product demand by end users. The decrease in unit volume was offset by an increase in
the per unit sales price recognized upon delivery of product to Abbott under the terms of our international distribution agreement.
Effective May 1, 2001, the terms of the distribution agreement (a) mandated an increase in the transfer price and (b) requires the
entire purchase price to be payable upon delivery of product to Abbott. Under the revised terms, the price earned by the Company is
essentially fixed or determinable at the time of delivery. Under the previous contract terms, the Company invoiced Abbott and
recognized revenue on sales to Abbott when Synagis was delivered based on a contractually stipulated transfer price, which
approximated 60 percent of the ultimate revenue value to us. Following the end of each quarter, Abbott remitted a report to us
detailing end-user sales for the quarter along with an additional amount due in excess of the transfer price. We recognized revenue
for the additional amount due in excess of the transfer price at that time. We have been working with Abbott to expand the number of
countries where we are licensed to sell Synagis. As of June 30, 2002, international registrations have been filed in 58 countries
for the approval of Synagis, for which approval in the United States and 47 foreign countries had been obtained, the most recent of
which was Canada in May 2002. There can be no assurance that approvals by the appropriate regulatory authorities will continue to be
granted. Additionally, we may not receive pricing and reimbursement approvals in countries where we have received regulatory
approval.
We have also achieved increases in Ethyol sales since we reacquired domestic marketing rights to Ethyol from ALZA Corporation
("ALZA") in October 2001. Ethyol accounted for approximately 29% and 11% of our second quarter product sales in 2002 and 2001,
respectively. Ethyol revenues increased from $3.1 million in second quarter of 2001 to $16.6 million in the second quarter of 2002.
Domestic Ethyol sales were $15.8 million in the 2002 quarter, as compared to $2.0 million in the 2001 quarter, due to an increase in
domestic sales unit volume of 138% and an increase in the sales price recorded in accordance with our assumption of domestic
marketing rights of the product from ALZA. As of October 1, 2001, we record all revenues from domestic sales of Ethyol and, as of
April 1, 2002, we began paying ALZA a declining royalty for nine years thereafter based on net sales of Ethyol in the U.S. Prior to
October 1, 2001, we had recorded Ethyol domestic product sales based on a price of 25% to 35% of ALZA's net unit selling price. Our
international sales of Ethyol to our distribution partner, Schering-Plough Corporation ("Schering"), of $0.8 million for the second
quarter of 2002 were down slightly from the prior year quarter sales of $1.1 million. We record Ethyol international product sales
based on a percentage of Schering's end user sales.
Sales of other products in second quarter 2002, which include sales of CytoGam, NeuTrexin, RespiGam, and by-products that result
from the CytoGam manufacturing process, were down. Second quarter CytoGam sales decreased to $7.0 million in 2002 from $7.6 million
in 2001. Unit sales decreased 18%, which was partially offset by a domestic price increase of 10% which took effect during the first
quarter of 2002. We expect that CytoGam sales for the year 2002 will be flat versus the prior year.
The level of future product sales will be dependent on several factors, including, but not limited to, the timing and extent of
future regulatory approvals of our products and product candidates, availability of finished product inventory, approval and
commercialization of competitive products and the degree of acceptance of our products in the marketplace.
Other Revenues - Other revenues for the quarter ended June 30, 2002 increased 26% to $6.4 million, from $5.1 million in the 2001
period, principally due to funding received in 2002 by MedImmune Vaccines for FluMist clinical and marketing activities of $3.8
million, net of decreases in revenue recorded under collaborative agreements in accordance with SAB 101. Other revenues during both
years include revenues under collaborative agreements. We recognized revenue of $1.9 million and $3.3 million for the second quarter
of 2002 and 2001, respectively, related to upfront and milestone payments under these agreements. For up-front and milestone
payments received prior to 2002, we recognized non-refundable fees and milestone payments in connection with research and
development and commercialization agreements as the contractual obligations and performance requirements are fulfilled, using the
contingency-adjusted performance model for revenue recognition. Under this method, the amount of revenue recognized during each
period is based on a percentage of completion model of actual costs incurred relative to the total projected costs. The expected
timing of annual revenues to be recognized through 2005 under the major collaborative agreements for which we have deferred a
portion of the upfront and milestone payments received, based on current estimates of costs to complete, is as follows (in
thousands):
2002 2003 2004 2005
------ ------ ---- ----
Abbott Laboratories $7,500 $2,700 $-- $--
GlaxoSmithKline 700 -- -- --
Schering-Plough Corporation 400 400 400 400
------ ------ ---- ----
Total $8,600 $3,100 $400 $400
====== ====== ==== ====
Future changes in estimated total costs or differences between actual costs and projected costs in any one period could cause the
actual recorded amounts to differ from the projected amounts. As discussed in "Critical Accounting Policies and Estimates - Contract
Revenues" above, we have adopted the milestone payment method for new contracts entered into after January 1, 2002. Since adopting
the new method, we have not entered into any new contracts in which we have received upfront or milestone payments. Because we have
adopted this method prospectively, the table above assumes the revenues deferred will be recognized in accordance with the
contingency adjusted performance model. The milestone payment method may not be applicable to all new contracts, in which case the
Company would revert to the contingency adjusted performance model for revenue recognition.
Other revenues in the 2002 period also includes $1.5 million under an agreement entered into during 2001 to sell excess production
capacity to a third party. Other revenues in the 2001 period also include $1.2 million from MGI Pharma related to the agreement for
the sale of our Hexalen business. The level of contract revenues in future periods will depend primarily upon the extent to which we
enter into other collaborative contractual arrangements, if any, and the extent to which we achieve certain milestones provided for
in existing agreements.
Cost of Sales - Cost of sales for the second quarter of 2002 increased 120% to $15.6 million from $7.1 million in 2001, principally
due to increases in sales volumes. Gross margins for the June 2002 quarter decreased to 73% from 75% in the June 2001 quarter
principally as a result of additional royalties payable relating to Synagis and the reverse royalty payable to ALZA on Ethyol,
effective April 2002. The increase in royalties was offset slightly by improved margins due to the implementation of an improved
manufacturing process at the Frederick Manufacturing Center ("FMC") which increases Synagis yields (the "enhanced yield process").
We expect that gross margins may vary significantly from quarter to quarter, based on the product mix. We expect that on an annual
basis, our gross margin percentage for 2002 should be lower than 2001, as a result of the additional royalties owed for Synagis and
Ethyol.
Research and Development Expenses - Research, development and clinical expenses increased $12.9 million, or 59% to $34.5 million in
the 2002 second quarter, from $21.7 million in the 2001 quarter. The increase reflects a larger number of active clinical trials and
the inclusion of on-going MedImmune Vaccines research, development and clinical expenses in our results. To accommodate the
additional activity, we expanded our workforce and facilities, resulting in increased wages and occupancy expense. Currently, our
clinical trial program includes eleven programs in various phases of clinical evaluation, including a Phase 3 study of Synagis in
infants with congenital heart disease and a trial in adults using a liquid formulation of Synagis; Phase 1 and Phase 2 trials with
our human papillomavirus (HPV) cervical cancer vaccine; Phase 2 trials with MEDI-507 in psoriasis patients; Phase 2 trials for our
urinary tract infection (UTI) vaccine; Phase 1 trials with Vitaxin in cancer and rheumatoid arthritis; and various trials for
FLUMIST. Additionally, we have eight programs in the pre-clinical stage.
We expect clinical spending to increase significantly over 2001 levels in the coming quarters as more of our product candidates move
into the clinic and we expand trials on products already in the clinic. In April 2002, we entered into a research collaboration with
A&G Pharmaceuticals, Inc. to license technology relating to PC-Cell Derived Growth Factor (PCDGF), a monoclonal antibody, the
initial indications of which would apply to breast cancer. In conjunction with the agreement, the Company is obligated to pay up to
$5.9 million in various milestone payments subject to the achievement of specified clinical, regulatory and sales milestones.
The development-stage efforts listed above and other research and development projects may never reach clinical trials, achieve
success in the clinic, be submitted to the appropriate regulatory authorities for approval, or be approved for marketing or
manufacturing by the appropriate regulatory authorities. Further, we rely on numerous third parties to assist us in various stages
of the development process. Should they be unable to meet our needs, we may incur substantial additional costs. Any of such
uncertainties, if they should occur, could have a material adverse effect on our financial condition and results of operations.
Selling, General, and Administrative Expense - Selling, general and administrative ("SG&A") expense increased $23.2 million, or
96% in the second quarter of 2002 to $47.4 million as compared to $24.2 million in the second quarter of 2001. The increase is
primarily attributable due to the inclusion of ongoing MedImmune Vaccines expenses as well as $1.9 million for amortization of
intangibles and $0.7 million for stock compensation expense for unvested stock options assumed in conjunction with the MedImmune
Vaccines merger. Additionally, we experienced increased costs for expanded Synagis marketing programs, sales commissions and
increased co-promotion expense to the Ross Products Division of Abbott Laboratories for the promotion of Synagis in the United
States. Both sales commissions and co-promotion expense are based on a percentage of net domestic sales of Synagis and thus increase
as net domestic Synagis sales increase. We also incurred increased salary and related expenses for the expansion of our Ethyol sales
force by adding approximately 40 additional sales representatives during the second half of 2001, and we increased our marketing
efforts for the relaunch of Ethyol. Additionally, we experienced increases in legal costs, as we are currently involved in several
litigation matters (see further discussion in the Legal Proceedings section of this report).
Other Operating Expenses - Other operating expenses increased in the 2002 quarter to $22.2 million from $3.5 million in the 2001
quarter. The increase is principally attributable to charges associated with MedImmune Vaccine's manufacturing operations for
FluMist, so as to be able to launch FluMist this fall, should FDA approval be granted. It is anticipated that these charges will
continue to be recorded to other operating expense so long as FluMist is under review by the FDA. In addition, we incurred $1.3
million in expense in the 2002 quarter relating to stock compensation for unvested stock options assumed and $2.2 million for
amortization of intangibles relating to our merger with MedImmune Vaccines. If and when FDA approval of FluMist is granted, a
significant portion of MedImmune Vaccines' manufacturing costs will be expensed to cost of sales. Also included in other operating
expense for both periods are costs associated with our Frederick manufacturing facility. The plasma production section of our
Frederick manufacturing facility has excess capacity, which results in charges to other operating expenses. These charges are
expected to continue for the foreseeable future until the plasma production section of the facility is fully utilized.
Interest Income and Expense - We earned interest income of $11.9 million during the 2002 quarter versus $9.0 million in the 2001
quarter, reflecting higher cash balances available for investment, due to the inclusion of MedImmune Vaccines' cash and investments
in our portfolio and cash generated from operations, partially offset by a decline in interest rates which lowered our portfolio
yield. Interest expense for the second quarter of 2002, net of amounts capitalized, increased $1.7 million over second quarter
2001. The increase relates to interest expense on MedImmune Vaccines' convertible debt included in our operating results.
Taxes - We recorded an income tax benefit of $16.5 million for the quarter ended June 30, 2002, resulting in an effective rate of
35.9%. This compares to a tax benefit of $5.1 million recorded for the quarter ended June 30, 2001, based on an effective tax rate
of 35.5%. The variation in the effective tax rate for 2002 versus 2001 results from differences in the amount of credits taken for
research and development programs and credits earned for orphan drug status of certain research and development activities. These
credits will vary from year to year depending on the activities of the Company. In addition, due to state tax law changes that
occurred during 2001, our statutory tax rate decreased to 37.0%. We believe that our year-to-date effective tax rate for 2002 will
be slightly below our statutory rate of 37.0%.
Net Loss - Net loss for the second quarter of 2002 was $29.5 million, or $0.12 per share, compared to a net loss for the 2001
quarter of $9.2 million, or $0.04 per share. Shares used in computing net loss per share for the quarter ended June 30, 2002 and
June 30, 2001 were 250.2 million and 213.1 million, respectively. The increase in share count primarily reflects the additional
shares issued in conjunction with the acquisition of MedImmune Vaccines.
Our quarterly financial results vary significantly due to seasonality of Synagis product sales, fluctuations in sales of other
products, milestone payments, research funding and expenditures for research, development, clinical and marketing programs. Synagis
sales are expected to occur primarily during, and in proximity to, the RSV season, which typically occurs between late September and
early May in the Northern Hemisphere. No assurances can be given that adequate product supply will be available to meet demand.
SIX MONTHS ENDED JUNE 30, 2002 AND 2001
Product Sales -
Product Sales (In Millions) 2002 2001
------ ------
Synagis $325.5 $236.5
Ethyol $34.8 $6.4
Other Products $17.7 $20.6
------ ------
TOTAL $378.0 $263.5
====== ======
Product sales grew 43% to $378.0 million in the six months ended June 30, 2002 from $263.5 million in the comparable 2001 period,
primarily driven by higher sales of Synagis, which accounted for 86% of our product sales for the six month period. Synagis sales
increased 38% from $236.5 million in the six months ended June 30, 2001 to $325.5 million in the six months ended June 30, 2002,
reflecting 40% growth in domestic unit sales due to increased demand for the product. Our international sales of Synagis decreased
32% primarily due to a decrease in units sold to Abbott International, ("Abbott") our exclusive distributor of Synagis outside of
the United States, and totaled $11.4 million in the 2002 six months versus $16.7 million in the 2001 six months. The Company
believes that the decrease is due to reductions in the inventory stocking levels of Abbott, rather than reduced product demand by
end users. The decrease in unit volume was offset by an increase in the per unit sales price recognized upon delivery of product to
Abbott under the terms of our international distribution agreement as is discussed in the product sales section of our analysis of
results for the three months ended June 30, 2002 and 2001.
Ethyol sales accounted for approximately 9% and 2% of year to date product sales in 2002 and 2001, respectively. Sales of Ethyol
increased from $6.4 million for the six months ended June 30, 2001 to $34.8 million for the six months ended June 30, 2002. The
increase is principally due to an increase in domestic sales unit volume of 124% and an increase in the sales price recorded in
accordance with our assumption of domestic marketing rights of the product. Domestic Ethyol sales were $32.6 million in the six
month 2002 period, as compared to $4.0 million in the 2001 comparable period. We reacquired domestic marketing rights to Ethyol from
ALZA in October 2001. Accordingly, as of October 1, 2001, we record all revenues from domestic sales of Ethyol and, as of April 1,
2002, we began paying ALZA a declining royalty for nine years thereafter based on net sales of Ethyol in the U.S. Prior to October
1, 2001, we had recorded Ethyol domestic product sales based on a price of 25% to 35% of ALZA's net unit selling price. Year to date
international sales of Ethyol to our distribution partner, Schering-Plough Corporation ("Schering"), of $2.2 million were down
slightly from the prior year sales of $2.5 million for the comparable period. We record Ethyol international product sales based on
a percentage of Schering's end user sales.
Sales of other products, which include sales of CytoGam, NeuTrexin, RespiGam, and by-products that result from the CytoGam
manufacturing process, decreased $2.9 million or 14% for the six months ended June 30, 2002 from the 2001 comparable period.
CytoGam sales for the six months ended June 30, 2002 fell 8% from the comparable 2001 period, principally due to a decrease in unit
sales of 22%. The decrease in domestic unit sales was partially offset by a 10% domestic price increase which took effect in the
first quarter of 2002. We expect that CytoGam sales for 2002 will be comparable with 2001 sales.
Other revenues - Other revenues in the six months ended June 30, 2002 of $15.4 million were comparable with other revenues for the
comparable 2001 period and consisted of $4.5 million of revenues recognized in accordance with SAB 101, $4.4 million relating to an
agreement entered into during 2001 to sell excess production capacity to a third party, $1.2 million from MGI Pharma related to the
agreement for the sale of our Hexalen business, and $4.3 million in grant income and reimbursement from Wyeth relating to our
collaborative agreement for FluMist. Other revenue for the 2001 six months includes $8.8 million of revenues recognized in
accordance with SAB 101, $2.4 million relating to the sale of our Hexalen business, $1.7 million for research funding from
GlaxoSmithKline for development of an HPV vaccine, and royalty income due from ALZA in accordance with the terms of the Ethyol
distribution agreement.
Cost of sales - Cost of sales for the 2002 six months increased 59% to $95.5 million from $59.9 million in the 2001 six months,
principally due to increases in sales volumes. Gross margins for the six month period ended June 30, 2002 were 75% versus 77% for
the six month period ended June 30, 2001. Gross margins decreased principally as a result of additional royalties payable relating
to Synagis. The increase in royalties was offset slightly by improved margins due to the implementation of the enhanced yield
process for the manufacture of Synagis. We expect that gross margins may vary significantly from quarter to quarter, based on the
product mix. We expect that on an annual basis, our gross margin percentage for 2002 should be lower than 2001, as a result of the
additional royalties owed for Synagis and Ethyol.
Research and Development Expenses - Research and development expenses of $78.6 million in the 2002 six months increased 95% from
$40.4 million in the 2001 six months, primarily due to higher expenditures on the Company's clinical trials and the inclusion of
on-going MedImmune Vaccines research, development and clinical expenses in our results, as well as $4.6 million in expense relating
to retention payments, stock option acceleration and stock compensation for unvested stock options assumed relating to our merger
with MedImmune Vaccines. To accommodate the additional activity, we expanded our workforce and facilities, resulting in increased
wages and occupancy expense. As discussed in the analysis of results for the three months ended June 30, 2002 above, we are
currently administering trials for eleven programs in various phases for our products and we have eight programs in the pre-clinical
stage. We expect clinical spending to increase in the coming quarters as we continue to move more of our product candidates into the
clinic and expand trials on products already in the clinic.
Selling, General and Administrative Expense- Selling, general and administrative expenses were $143.0 million and $83.9 million for
the 2002 and 2001 periods, respectively, an increase of 70%. As a percentage of product sales, SG&A expense increased to 38% of
product sales in the 2002 period from 32% in the 2001 period. The increase in this ratio is largely reflective of ongoing expenses
relating to MedImmune Vaccines, which, to date, has no product sales. SG&A expense also includes $2.3 million in expense in the
2002 six month period relating to retention payments, stock option acceleration and stock compensation for unvested stock options
assumed and $3.6 million for amortization of intangibles in conjunction with the MedImmune Vaccines merger. Additionally, we
incurred increased costs for expanded Synagis marketing programs, sales commissions and increased co-promotion expense to the Ross
Products Division of Abbott Laboratories for the promotion of Synagis in the United States. Co-promotion expense is based on a
percentage of net domestic sales of Synagis and thus increases as net domestic Synagis sales increase. In 2002, we also incurred
increased salary and related expenses for the expansion of our Ethyol sales force by adding approximately 40 additional sales
representatives during the second half of 2001 and increased marketing expenses for the relaunch of Ethyol. Additionally, we
experienced increases in legal costs, as we are currently involved in several litigation matters (see further discussion in the
Legal Proceedings section of this report).
Other Operating Expense- Other operating expenses increased to $44.0 million in the six months ended June 30, 2002 from $5.6 million
in the 2001 period. The increase is principally attributable to charges associated with MedImmune Vaccines' manufacturing operations
for FluMist, so as to be able to launch FluMist this fall, should FDA approval be granted. It is anticipated that these charges will
continue to be recorded to other operating expense so long as FluMist is under review by the FDA. In addition, we incurred $6.9
million in expense in the 2002 six month period relating to retention payments, stock option acceleration and stock compensation for
unvested stock options assumed and $4.2 million for amortization of intangibles relating to our merger with MedImmune Vaccines. If
and when FDA approval of FluMist is granted, a significant portion of MedImmune Vaccines' manufacturing costs will be expensed to
cost of sales. Also included in other operating expense for both periods are costs associated with our Frederick manufacturing
facility. The plasma production section of our Frederick manufacturing facility has excess capacity, which results in charges to
other operating expenses. These charges are expected to continue for the foreseeable future until the plasma production section of
the facility is fully utilized.
In-Process Research and Development - We incurred charges of $1,179.3 million during the six month period ended June 30, 2002 for
the write-off of purchased in-process research and development in conjunction with our acquisition of Aviron. The write-off
represents the fair value of purchased in-process technologies at the acquisition date, calculated utilizing the sum of the
probability-adjusted scenarios under the income approach using a discount rate of 18.7%, and certain in-process research and
development projects, primarily FluMist. The Company does not anticipate that there will be any alternative future use for the
in-process technologies that were written off.
FluMist is a live, attenuated vaccine delivered via a nasal mist for the prevention of influenza. We are currently seeking
regulatory approval for the frozen formulation, which requires freezer storage. The liquid formulation of FluMist, which is better
suited to international markets than the frozen formulation, is currently in Phase 3 clinical trials with our international partner,
Wyeth. While there are other flu vaccines currently marketed by other companies, FluMist would be the only live virus vaccine
administered as a nasal mist available in the United States. As of the date of the merger, Aviron had submitted a biologic license
application ("BLA") for FluMist (frozen) to the FDA seeking approval for licensure. The BLA was submitted to the FDA in October
2000. Aviron received a Complete Response Letter from the FDA on August 31, 2001, and filed its response to this letter on January
8, 2002. A second Complete Response Letter was received from the FDA on July 10, 2002 requesting clarification and additional
information relating to clinical data and chemistry, manufacturing and controls data previously submitted. We intend to submit a
response to the Complete Response Letter during August 2002. The Company hopes to achieve approval of the product for either the
2002 or the 2003 flu season; however, we cannot guarantee that approval will be obtained at all. If FluMist is not approved in 2002,
projected revenues for the full year 2002 would be reduced by approximately $100 million to $110 million and earnings per share by
about $0.25 to $0.27.
The valuation of the acquired in-process research and development is based upon certain estimates and assumptions by management. The
valuation is based upon management's estimates of the probability of FDA approval and commercial success for FluMist. As with all
biotechnology products, the probability of FDA approval and commercial success for any particular research and development project
is highly uncertain. Management's projections were based on assumptions, which may or may not remain valid for the relevant period,
including the estimated impact of four "key" factors: price per dose; dose volumes; launch date; and the potential failure of the
frozen or liquid formulations of FluMist. Based on current information, management believes that the estimates and assumptions
underlying the fair value analysis are substantially accurate. In addition, as of June 30, 2002, none of the existing manufacturing
facilities involved in the production of FluMist had been licensed by any regulatory agency and FluMist had not yet been
manufactured at a sustained commercial scale. There can be no assurance that these facilities can achieve licensure by the FDA or
any other regulatory agency. Nor can there be any assurances that if licensed, commercial scale production could be achieved or
sustained. If we fail to obtain FDA approval for the marketing and manufacture of FluMist, we will absorb all of MedImmune Vaccines'
ongoing expenses while recording no corresponding revenue.
Interest Income and Expense - We earned interest income of $23.8 million for the first six months of 2002, versus $19.2 million in
the comparable 2001 period, reflecting higher cash balances available for investment due to operating cash flows and the inclusion
of MedImmune Vaccines' cash and investments, partially offset by a decrease in interest rates which lowered the overall portfolio
yield. Interest expense for the first half of 2002, net of amounts capitalized, increased $4.3 million over the first half of 2001
due to interest expense on MedImmune Vaccines' convertible debt included in our operating results.
Taxes- We recorded income tax expense of $18.4 million for the six months ended June 30, 2002. Excluding the write-off of purchased
in-process research and development and other insignificant items, which are not deductible for tax purposes, income tax expense
resulted in an effective tax rate of 35.7%. This compares to tax expense for the six months ended June 30, 2001 of $38.2 million,
resulting in an effective rate of 35.5%. The variation from the statutory rate in both periods is principally due to the amount of
credits taken for research and development expenditures and credits earned for Orphan Drug status of certain research and
development expenses. In addition, due to state tax law changes that occurred during 2001, our statutory tax rate decreased to
37.0%. We believe that our year-to-date effective tax rate for 2002 will be slightly below our statutory rate of 37.0%.
Net Loss - Net loss for the first half of 2002, which includes the impact of the write off for in- process research and development,
was $1,146.3 million or $4.62 per share. Shares used in computing net loss per share were 248.1 million. This compared to net
earnings for the first half of 2001 of $69.4 million or $0.33 basic and $0.32 diluted earnings per share. Shares used in computing
basic and diluted earnings per share were 212.7 million and 219.9 million, respectively. The increase in share count primarily
reflects the additional shares issued in conjunction with the acquisition of MedImmune Vaccines.
LIQUIDITY AND CAPITAL RESOURCES
Sources and uses of cash- The Company's capital requirements have generally been funded from operations, cash and investments on
hand, and issuance of common stock. Cash and marketable securities were $1,354.1 million at June 30, 2002 versus $787.7 million
December 31, 2001, an increase of 72%. Increases in cash are due to cash generated by operations and cash acquired in conjunction
with the MedImmune Vaccines merger. Working capital increased to $566.1 million at June 30, 2002, from $429.9 million at December
31, 2001.
Operating Activities
Net cash provided by operating activities decreased to $155.0 million in the six months ended June 30, 2002 as compared to $169.2
million in the comparable 2001 period, primarily as the result of the net loss for the period (excluding the write-off of in-process
research and development and other non-cash items), and decreases in accrued expenses, primarily as a result of payments of amounts
due to Abbott for co-promotion of Synagis, and decreases in royalties payable, offset by decreases in accounts receivable. The
Company also expended cash for restructuring payments relating to the MedImmune Vaccines acquisition. The remaining restructuring
liability of $1.4 million is expected to be settled by 2004. Payments are expected to be made from cash generated from operations.
Investing Activities
Cash used for investing activities during the first half of 2002 amounted to $274.5 million, as compared to $202.1 million in 2001.
Cash used for investing activities in 2002 included net additions to our investment portfolio of $379.9 million, offset by $146.9 in
cash acquired as a result of our merger with MedImmune Vaccines. We also invested $3.7 million in preferred equity securities of two
strategic partners: Panacea, which is developing the HAAH technology; and A&G Pharmaceuticals Inc. (A&G), which is
developing the PC-Cell Derived Growth Factor (PCDGF) technology. We expended $37.7 million for capital expenditures, primarily for
the construction of our new corporate headquarters, and for the continued expansion of our manufacturing facilities in Frederick and
the MedImmune Vaccines facilities in the U.K. and Philadelphia, Pennsylvania.
During March 2002, we paid approximately $13.4 million to acquire 11 acres of land in Gaithersburg, Maryland, which will serve as
the site of our new corporate headquarters. Additionally, the Company has options to purchase an additional 14 acres of land. We
have contracted with a designer and general contractor for the construction of the first phase of the new facility, at a total
estimated cost of $85 million, to be funded from net cash from operations and investments on hand. Construction began during March
2002, and the Company expects to take occupancy of the first phase, a complex of approximately 218,000 square feet, in the fall of
2003. At that time, the Company expects to sublease a substantial portion of its existing space. There can be no guarantee that we
will be successful in subleasing the space.
In conjunction with the research and development collaborations with Panacea and A&G, the Company is obligated to pay up to
$40.0 million in various milestone payments subject to the achievement of specified clinical, regulatory, and sales milestones and
is obligated to make quarterly research and development funding payments. Payments due are expected to be funded from net cash from
operations and investments on hand.
Financing Activities
Financing activities generated $37.8 million in cash for the first half of 2002, as compared to $16.0 million in 2001. Approximately
$38.1 million was received upon the issuance of common stock and exercise of employee stock options in 2002, as compared to $16.4
million received in 2001, largely reflecting the inclusion of option exercises of MedImmune Vaccines subsequent to the acquisition.
In 2002 and 2001, repayments on long-term debt were $0.4 million.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Following the Company's acquisition of MedImmune Vaccines, MedImmune Vaccines remains obligated for its outstanding indebtedness,
which included $200.0 million aggregate principal amount of 5 1/4% Convertible Subordinated Notes (the "Notes") due 2008. The Notes
were recorded at fair value of $211.4 million, based on quoted market prices as of January 10, 2002, the acquisition date. Interest
is payable semi-annually in arrears in cash on February 1 and August 1 each year. Changes in interest rates do not affect interest
expense incurred on the Notes, because they bear interest at fixed rates. The Notes are convertible into an aggregate of 3.4
million shares of the Company's common stock, based on a conversion price of $58.14, at any time on or before February 1, 2008.
MedImmune Vaccines may redeem the Notes beginning in February 2004, at the redemption prices declining from 103% of their principal
amount in 2004 to 100% in 2008, plus accrued interest.
The Company periodically enters into foreign exchange forward contracts which permit the Company to purchase Euros to fund a portion
of its inventory purchase obligations at a fixed exchange rate. As of June 30, 2002, the Company had outstanding forward Euro
contracts in the amount of $5.4 million, all expiring within one year. Fair value of the outstanding contracts at June 30, 2002 was
$0.7 million.
As of June 30, 2002 we have invested approximately $20.1 million with strategic partners in various forms of investments,
principally preferred equity securities and convertible preferred equity securities. In accordance with Accounting Principles
Generally Accepted in the United States of America, we carry the majority of these investments at cost, adjusted for any
other-than-temporary declines in value. We evaluate these investments on a quarterly basis, and adjust the carrying value for
other-than-temporary impairments if necessary. During 2002, we reduced the cost basis of one of our investments by $0.3 million due
to an other-than temporary impairment. Should this investment or any of our other investments experience an other-than-temporary
impairment, further write downs could occur, up to the total amount of our investment. Additionally, the Company maintains one
investment in accordance with the equity method. The equity method of accounting requires us to adjust the carrying value of our
investment for our proportionate share of the gains or losses generated by the investee on a quarterly basis. As of June 30, 2002 we
wrote down this investment by $0.1 million. Our total investment is now $2.1 million. Further writedown of our investment could
occur, up to our total investment, should the investee continue to incur net losses in future periods.
In July 2002, the Company formed MedImmune Ventures, Inc., a wholly-owned venture capital subsidiary that will invest in
early-to-late-stage public or private biotechnology companies focused on discovering and developing human therapeutics. The fund
will invest primarily in areas of strategic interest to the Company, including infectious disease, immunology and oncology. The fund
initially plans to invest up to $100.0 million over the next three years. In accordance with accounting principles generally
accepted in the United States of America, the investments will likely be maintained either on the cost or equity method of
accounting, according to the facts and circumstances of the individual investment. Under either method, the investments will be
subject to adjustment for other-than-temporary impairments. In addition, investments accounted for under the equity method will be
adjusted for the Company's proportionate share of the investee's gains or losses on a quarterly basis.
For other information regarding the Company's market risk exposure, please refer to Part II, Item 7A., "Quantitative and Qualitative
Disclosures About Market Risk" of the Company's Annual Report on Form 10-K for the year ended December 31, 2001.
--------------------
The statements in this quarterly report that are not descriptions of historical facts may be forward-looking statements. Those
statements involve substantial risks and uncertainties. You can identify those statements by the fact that they contain words such
as "anticipate," "believe," "estimate," "expect," "intend," "project" or other terms of similar meaning. Those statements reflect
management's current beliefs, but are based on numerous assumptions which MedImmune cannot control and which may not develop as
MedImmune expects. Consequently, actual results may differ materially from those projected in the forward - looking statements.
Among the factors that could cause actual results to differ materially are: seasonal demand for and continued supply of the
Company's principal product, Synagis; whether FluMist receives clearance by the Food and Drug Administration and, if it does,
whether it will be successfully launched; availability of competitive products in the market; availability of third-party
reimbursement for the cost of our products; effectiveness and safety of our products; exposure to product liability, intellectual
property or other types of litigation; foreign currency exchange rate fluctuations; changes in generally accepted accounting
principles; growth in costs and expenses; the impact of acquisitions, divestitures and other unusual items; and the risks,
uncertainties and other matters discussed in this quarterly report and in our periodic reports filed with the U.S. Securities and
Exchange Commission. MedImmune cautions that RSV disease occurs primarily during the winter months; MedImmune believes its operating
results will reflect that seasonality for the foreseeable future. MedImmune is also developing several products (including FluMist)
for potential future marketing. There can be no assurance that such development efforts will succeed, that such products will
receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately
achieve commercial success. Unless otherwise indicated, the information in this quarterly report is as of June 30, 2002. This
quarterly report will not be updated as a result of new information or future events.
PART II
OTHER INFORMATION
Item 1. Legal Proceedings
In 1998, MediGene AG ("MediGene") initiated a legal action against Loyola University of Chicago ("Loyola") and the Company in the
U.S. District Court for the Northern District of Illinois alleging, among other things, breach of contract and tortious interference
by the Company with an alleged prospective business relationship between MediGene and Loyola. The claims relate to human
papillomavirus vaccine technology allegedly covered by contracts between MediGene and the Company and by a license agreement from
Loyola to the Company, under which the Company granted a sublicense to GlaxoSmithKline. MediGene seeks damages from the Company
ranging from $31.3 million to $86.9 million based on the tortious interference claim, and/or damages ranging from $10.2 million to
$31.3 million based on the breach of contract claim. MediGene also seeks ownership of the patents in question, as well as rescission
of the Company's license agreement from Loyola or rights as a third-party beneficiary thereof. On December 22, 2000 and March 15,
2001, the District Court granted summary judgment motions in favor of the Company on all claims. The District Court ordered entry of
final judgment in favor of the Company on March 19, 2002. On March 27, 2002 MediGene filed a notice of appeal to the United States
Court of Appeals for the Federal Circuit. On or about June 27, 2002, the Federal Circuit Court transferred the appeal to the United
States Court of Appeals for the Seventh Circuit. MediGene's brief will be due August 12, 2002, and Loyola and the Company's brief
will be due September 11, 2002.
In October 2000, Celltech Chiroscience Limited ("Celltech") commenced a legal proceeding against the Company in the U.K. High Court
of Justice, Chancery Division, Patents Court. Celltech alleges that the Company failed to pay royalties with respect to its sales of
Synagis as required by a license agreement dated January 19, 1998. Under the agreement, the Company obtained from Celltech a
worldwide license to make, use and/or sell product under a patent (and related applications) pertaining to humanized antibodies. In
the proceeding, Celltech seeks payment of a 2% royalty based on net sales of Synagis sold or manufactured in the United States, with
interest, and certain costs, including attorney's fees. The Company has filed answering papers denying that any royalties are due on
the basis that Celltech's U.S. patent does not cover Synagis and has sought dismissal of the case on the grounds that the legal
doctrine of prosecution history estoppel prevents Celltech from claiming that its patent covers Synagis. On July 20, 2001, the High
Court of Justice ordered a hearing, which is scheduled to begin on October 1, 2002, on whether it will dismiss Celltech's case on
this basis. On November 29, 2001, the Company received a letter from counsel for Celltech enclosing a copy of a patent granted by
the European Patent Office on November 14, 2001. That letter requested various information concerning the manufacture and sale of
Synagis in Europe and sought confirmation that the Company would pay royalties on such sales pursuant to the license agreement dated
January 19, 1998. As of August 9, 2002, the Company had not made the royalty payments that were the subject of Celltech's letter,
and Celltech had not initiated any legal proceeding against the Company based on its European patent.
On December 18, 2001, Genentech, Inc. ("Genentech") announced that it had been granted a patent relating to certain methods and
compositions used to produce antibodies by recombinant DNA technology. In June 1997, in anticipation of any potential impact the
issuance of Genentech's patent could have on the production of Synagis, the Company obtained a license to this patent. The Company
has received from Genentech a letter, dated January 7, 2002, stating that Genentech expects to receive from the Company royalty
payments pursuant to such license. The Company is in the process of evaluating whether any valid claim of Genentech's patent, as
recently issued, covers production of Synagis. If so, the Company would pay royalties to Genentech on U.S. net sales of Synagis
commencing December 18, 2001. Pending resolution of this issue, the Company has made certain royalty payments to Genentech under
protest and with reservation of all of its rights. The Company is also evaluating whether any of its other antibody-based product
candidates, if and when approved for marketing by the U.S. Food and Drug Administration, could require a license under the Genentech
patent.
On February 28, 1996, Ichthyol Gesellschaft Cordes, Hermanni & Co. ("Ichthyol Gesellschaft") filed a complaint for refrain,
information and damages with the Regional Court of Hamburg against MedImmune Oncology on the grounds of trademark infringement in
respect of the use of the trademark "Ethyol" in Germany. No monetary amount is currently being sought in the litigation by Ichthyol.
Ichthyol is seeking injunctive relief against the use of the trademark Ethyol in Germany. The suit was dismissed on January 29, 1997
by the Regional Court of Hamburg. Ichthyol Gesellschaft filed an appeal and a judgment was rendered in favor of MedImmune Oncology
in the appellate proceedings. In January 1999, Ichthyol Gesellschaft filed an appeal on points of law with the Federal Court of
Justice, and in June 1999, Ichthyol Gesellschaft filed the grounds for the appeal on points of law. By judgment of May 3, 2001, the
Federal Court of Justice reversed the judgment of the Higher Regional Court and remitted the case to that court for another hearing.
By order of December l9, 2001, the Higher Regional Court ordered Ichthyol to make further submissions concerning the relevant facts
and legal questions. Ichthyol recently filed its submissions. Another hearing will probably be held this fall.
The Company is currently involved in a dispute over the RSV License Agreement ("License Agreement") between the Company and
University of Massachusetts Biologic Laboratories ("MBL"), executed in 1989. Under the License Agreement, the Company granted MBL an
exclusive, royalty free license to "make, have made, use and sell" the Company's monoclonal antibody for RSV for use only in the
Commonwealth of Massachusetts and the State of Maine. The Company further agreed to transfer to MBL sufficient information and to
provide sufficient technical assistance to enable MBL to apply the Company's monoclonal antibody to MBL's manufacturing operations.
MBL now alleges that the Company has not provided sufficient information or sufficient technical assistance to enable MBL to
manufacture the Company's monoclonal antibody for RSV. In addition, MBL has claimed that the Company's Distribution Agreement with
Abbott International, Ltd. ("Abbott"), under which Abbott is the exclusive distributor of Synagis overseas, constitutes a
"sub-license" under the terms of the License Agreement and thus MBL claims a right to a larger share of the proceeds derived by the
Company from the Distribution Agreement. The Company disputes the allegations made by MBL and believes MBL's claims to be without
merit. The Company and MBL are currently in the process of mediating their dispute to determine whether a mutually agreeable
solution can be achieved. There can be no assurance that this dispute can be resolved without litigation.
On April 5, 2002, the Company filed a suit against Centocor, Inc. ("Centocor") in the United States District Court for the District
of Maryland. The Company currently pays Centocor a royalty for sales of Synagis made or sold in the United States pursuant to a
patent Sublicense Agreement between the parties dated as of September 15, 2000 (the "Sublicense Agreement"). In the litigation, the
Company seeks a declaratory judgment that it has no obligation to continue paying royalties to Centocor on the basis that the patent
is invalid, unenforceable and does not cover Synagis. Additionally, the Company seeks an injunction preventing Centocor from
enforcing this patent. On July 1, 2002, Centocor moved to dismiss this action on the basis that it did not include the Trustees of
Columbia University in the City of New York ("Columbia") and the Board of Trustees of the Leland Stanford University ("Stanford"),
as the owners of the patent. On July 9, 2002, Centocor, Columbia and Stanford initiated an action against the Company in the United
States District Court for the Northern District of California. In the California litigation, Centocor, Columbia and Stanford seek a
declaratory judgment that the patent at issue in the Sublicense Agreement is valid and enforceable and that the Company would be
liable for patent infringement but for the Sublicense Agreement, as well as a declaratory judgment that the Sublicense Agreement is
enforceable. There can be no assurance that the Company will be successful in this litigation.
After consultation with its counsel, the Company believes that it has meritorious defenses to the claims against it referred to
above and is determined to defend its position vigorously. While it is impossible to predict with certainty the eventual outcome of
these proceedings, the Company believes they are unlikely to have a material adverse effect on its financial position but might have
a material adverse effect on its results of operations for a particular period.
Item 2. Changes in Securities - None
Item 3. Defaults upon Senior Securities - None
Item 4. Submission of Matters to a Vote of Security Holders
On May 23, 2002 the Company held its Annual Meeting of Stockholders. By vote of the Company's stockholders at such meeting, all of
the director nominees were re-elected to one year terms. A proposal to increase the number of shares authorized under the Company's
1999 Stock Option Plan from 19,250,000 to 25,250,000 and the appointment of PricewaterhouseCoopers LLP as the Company's independent
auditors were also approved. The results of the voting were as follows:
Election of Directors
Abstain/
For Against Withheld Non-vote
Wayne T. Hockmeyer 207,244,641 -- 1,750,883 --
David M. Mott 207,244,632 -- 1,750,892 --
Melvin D. Booth 207,112,074 -- 1,883,450 --
Franklin H. Top, Jr. 207,244,671 -- 1,750,853 --
M. James Barrett 206,201,721 -- 2,793,803 --
James H. Cavanaugh 207,244,611 -- 1,750,913 --
Barbara H. Franklin 206,201,461 -- 2,794,063 --
Gordon S. Macklin 206,201,721 -- 2,793,803 --
Elizabeth Wyatt 205,363,437 3,632,087
To approve an amendment to the 1999 Stock Option
Plan 196,175,465 9,663,966 -- 3,156,096
Appointment of PricewaterhouseCoopers LLP
as independent auditors 199,731,914 8,498,835 -- 757,745
Item 5. Other Information - None
Item 6. Exhibits and reports on Form 8-K
(a) Exhibits:
99.1 Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of
the Sarbanes-Oxley Act of 2002.
99.2 Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of
the Sarbanes-Oxley Act of 2002.
(b) Reports on Form 8-K:
Report Date Event Reported
----------- --------------
July 10, 2002 MedImmune issues 2001 financial statements of Aviron and proforma financial information
in connection with its acquisition of Aviron.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.
MEDIMMUNE, INC.
(Registrant)
/s/ Gregory S. Patrick
Date: August 13, 2002 Gregory S. Patrick
Senior Vice President and Chief Financial Officer